Cala Health, a bioelectronic medicine company focused on treating neurological conditions, has secured $50 million in growth capital from Trinity Capital to support expansion and product development. The California-based company develops wearable therapies designed to help patients manage chronic conditions such as Parkinson’s disease and essential tremor.
Its core product is a prescription wearable device that uses transcutaneous afferent patterned stimulation (TAPS) to reduce hand tremors. The technology works by analysing an individual patient’s tremor patterns and delivering targeted nerve stimulation, allowing for personalised therapy that can be used at home. The approach offers a non-invasive alternative for managing symptoms that can significantly impact daily functioning.
Cala Health has received multiple 510(k) clearances from the Food and Drug Administration, including its latest device, Cala kIQ Plus, which is designed to provide temporary relief from tremors associated with both essential tremor and Parkinson’s disease. The company has steadily built momentum with previous funding rounds, including $77 million raised in 2021 and a $55 million Series B in 2019.
With the new funding, Cala aims to accelerate commercial growth and continue advancing its neuromodulation technology, positioning wearable therapies as a scalable option for managing chronic neurological disorders.
Click here to read the original news story.
